Related Experiment Videos
Transcutaneous immunization and immunostimulant strategies.
Gregory M Glenn1, Richard T Kenney, Scott A Hammond
1IOMAI Corporation, 20 Firstfield Road, Suite 250, Gaithersburg, MD 20878, USA. gglenn@iomai.com
Immunology and Allergy Clinics of North America
|February 3, 2004
Summary
Skin vaccination using microneedle patches offers a safe and effective method for delivering antigens and adjuvants. This approach leverages the skin's immune environment to elicit robust immune responses, paving the way for future vaccine development.
Area of Science:
- Immunology
- Dermatology
- Vaccinology
Background:
- The skin offers a unique immune microenvironment suitable for vaccine delivery and adjuvant administration.
- Langerhans cells (LCs), a type of dendritic cell, are hypothesized to stimulate potent immune responses upon adjuvant activation, a theory now gaining validation.
Purpose of the Study:
- To validate the potential of skin-based vaccine delivery systems.
- To optimize antigen and adjuvant formulations for transcutaneous immunization (TCI) patches.
- To establish the safety and efficacy of TCI for delivering large protein antigens.
Main Methods:
- Development of simple skin pretreatment protocols compatible with existing practices.
- Optimization of antigen and adjuvant formulations for microneedle patch delivery.
- Clinical testing of formulated, manufacturable patches in Phase 2 trials.
Main Results:
- Demonstrated successful clinical delivery of large protein antigens via TCI patches.
- Achieved robust and safe immune responses in participants.
- Established the underlying biological principles for TCI and the IS patch technology.
Conclusions:
- Transcutaneous immunization (TCI) using microneedle patches is a viable strategy for safe and effective vaccine delivery.
- Further development is required to optimize the technology for specific vaccine applications over the next five years.